Cabotegravir for PrEP Not Associated With Weight Gain in HIV-Uninfected Individuals

Article

Weight gain is often a concern for patients on ART. But what about the metabolic impact of PrEP on HIV-uninfected individuals?

Weight gain can be an unpleasant side effect of some antiretroviral therapy treatment regimens containing integrase inhibitors. With the rise in pre-exposure prophylaxis (PrEP) for HIV-uninfected individuals, there is a need to determine whether similar metabolic side effects exist.

Investigators of HPTN 077, a phase 2a randomized, placebo-controlled study of 2 dose/dose-interval regimens of oral and injectable cabotegravir in HIV-uninfected individuals, found no association between cabotegravir and weight gain in persons without HIV.

The findings of the study were presented today, March 5, 2019, as a late breaker in an oral abstract session at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019).

A total of 199 HIV-negative male and female participants from 8 sites in the United States, Brazil, and sub-Saharan Africa were enrolled and randomized 3:1 to receive active cabotegravir or placebo. The participants received oral cabotegravir 30 mg or placebo once a day for 4 weeks, a 1-week washout, and then sequential injections of long-acting cabotegravir or 0.9% saline placebo from week 5 through week 41.

Baseline weight assessments were conducted, as well as assessments of body mass index (BMI), smoking status, age, and race/ethnicity. Weight was then measured during the oral product administration and injectable study administration.

Median weight change over 41 weeks was +1.1 kg (2.42 pounds) (IQR 0.9, 3.0) in the cabotegravir arm and +1.0 kg (IQR -1.2, 3.2) in the placebo arm (p = .66). Therefore, there was no difference in weight change for participants receiving cabotegravir or placebo.

“In longitudinal statistical analyses, no statistically significant differences were found in change in weight from [week] 0 to 41 in cabotegravir vs. placebo treated participants in aggregate, by sex, dosing cohort, age, race/ethnicity, smoking status, BMI, nor by baseline BMI category,” investigators concluded in the study abstract. “No differences in weight change for cabotegravir vs. placebo were seen for [week] 0-4 and [week] 5-41 separately.”

The study, “Cabotegravir Is Not Associated With Weight Gain in HIV-Negative Individuals: HPTN 077,” was presented on Tuesday, March 5, 2019, at CROI 2019 in Seattle, Washington.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.